Company Description
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
Its lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis.
The company is also developing ARQ-154, a topical ZORYVE foam for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-255, a selective small molecule inhibitor of JAK1 for the treatment of alopecia areata; ARQ-252, a JAK1-selective topical cream in development for hand eczema and vitiligo; and ARQ-234, a CD200R fusion protein for the treatment of atopic dermatitis.
The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019.
Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Country | United States |
Founded | 2016 |
IPO Date | Jan 31, 2020 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 342 |
CEO | Todd Watanabe |
Contact Details
Address: 3027 Townsgate Road, Suite 300 Westlake Village, California 91361 United States | |
Phone | 805 418 5006 |
Website | arcutis.com |
Stock Details
Ticker Symbol | ARQT |
Exchange | NASDAQ |
Stock Type | Common Stock |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $17.00 |
CIK Code | 0001787306 |
CUSIP Number | 03969K108 |
ISIN Number | US03969K1088 |
Employer ID | 81-2974255 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Todd Franklin Watanabe M.A. | President, Chief Executive Officer and Director |
Dr. Bhaskar Chaudhuri Ph.D. | Co-Founder and Independent Director |
Masaru Matsuda Esq., J.D. | Senior Vice President, General Counsel and Corporate Secretary |
Dr. Patrick E. Burnett M.D., Ph.D. | Executive Vice President and Chief Medical Officer |
Larry Todd Edwards | Executive Vice President and Chief Commercial Officer |
Latha Vairavan | Chief Financial Officer |
Rajvir Madan | Chief Digital and Technology Officer |
Amanda Sheldon | Head of Corporate Communications |
Kent Taylor | Senior Vice President of Sales |
Aleen Hosdaghian | Vice President of Marketing |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jul 1, 2025 | 144 | Filing |
Jun 18, 2025 | 144 | Filing |
Jun 17, 2025 | 8-K | Current Report |
May 28, 2025 | 144 | Filing |
May 19, 2025 | 144 | Filing |
May 15, 2025 | SCHEDULE 13G/A | Filing |
May 15, 2025 | SCHEDULE 13G/A | Filing |
May 8, 2025 | SCHEDULE 13G/A | Filing |
May 8, 2025 | 144 | Filing |
May 6, 2025 | 10-Q | Quarterly Report |